Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Unloaded Rep. Jonathan L. Jackson

Representative Jonathan L. Jackson (D-Illinois) recently sold shares of Regeneron Pharmaceuticals, Inc. NASDAQ: REGN. In a filing disclosed on December 12th, the Representative disclosed that they had sold between $15,001 and $50,000 in Regeneron Pharmaceuticals stock on November 13th. The trade occurred in the Representative's "MORGAN STANLEY TRUST ACCOUNT" account.

Representative Jonathan L. Jackson also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Amazon.com NASDAQ: AMZN on 11/27/2024.
• Sold $15,001 - $50,000 in shares of Applied Materials NASDAQ: AMAT on 11/27/2024.
• Purchased $15,001 - $50,000 in shares of Church & Dwight NYSE: CHD on 11/13/2024.
• Sold $1,001 - $15,000 in shares of Regeneron Pharmaceuticals NASDAQ: REGN on 11/1/2024.
• Purchased $15,001 - $50,000 in shares of Salesforce NYSE: CRM on 10/28/2024.
• Sold $15,001 - $50,000 in shares of ASML NASDAQ: ASML on 10/28/2024.
• Purchased $15,001 - $50,000 in shares of General Dynamics NYSE: GD on 9/24/2024.
• Sold $15,001 - $50,000 in shares of Merck & Co., Inc. NYSE: MRK on 9/24/2024.
• Purchased $15,001 - $50,000 in shares of Aramark NYSE: ARMK on 9/19/2024.
• Sold $15,001 - $50,000 in shares of AES NYSE: AES on 9/19/2024.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $9.67 on Friday, reaching $731.30. The stock had a trading volume of 696,989 shares, compared to its average volume of 847,429. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market cap of $80.36 billion, a P/E ratio of 18.10, a price-to-earnings-growth ratio of 2.19 and a beta of 0.08. The firm has a fifty day moving average of $849.77 and a two-hundred day moving average of $1,004.02. Regeneron Pharmaceuticals, Inc. has a 1-year low of $728.68 and a 1-year high of $1,211.20.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. International Assets Investment Management LLC grew its position in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after buying an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at $127,489,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company's stock valued at $525,804,000 after purchasing an additional 96,266 shares during the period. TD Asset Management Inc boosted its position in shares of Regeneron Pharmaceuticals by 30.4% during the 2nd quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company's stock worth $369,484,000 after purchasing an additional 82,034 shares in the last quarter. Finally, Icon Wealth Advisors LLC increased its position in Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company's stock valued at $79,874,000 after buying an additional 75,569 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating on the stock in a research report on Tuesday, October 22nd. StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, November 4th. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. reduced their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating on the stock in a research report on Thursday, October 24th. Finally, Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $1,099.90.

About Representative Jackson

Jonathan Jackson (Democratic Party) is a member of the U.S. House, representing Illinois' 1st Congressional District. Jackson assumed office on January 3, 2023. Jackson's current term ends on January 3, 2025. Jackson (Democratic Party) is running for re-election to the U.S. House to represent Illinois' 1st Congressional District. Jackson declared candidacy for the 2024 election. Jonathan Jackson was born in Chicago, Illinois. Jackson graduated from Whitney Young High School. He earned an M.B.A. from Northwestern University. Jackson's career experience includes working as an investment analyst and an entrepreneur.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.